MDD Augmentation: Atypical Antipsychotics

It is known that close to 50% of patients with major depressive episodes may not achieve remission after the trials of first-line antidepressants, and only around one-third will achieve remission. This is clinically relevant for both patients and medical professionals, as chances of remission reduce with each subsequent trial. 

Psychiatry Education Forum Academy is excited to release the first chapter of our lecture series on 10 Augmentation Strategies for MDD.

The first lecture in this series is on Atypical Antipsychotics. Atypical antipsychotics are recommended by most guidelines as an augmentation treatment for major depressive disorders. 

Let’s begin with this question:

Which of the following atypical antipsychotic is not FDA approved for MDD augmentation but is recommended as first line for MDD augmentation by CANMAT and British Association of Psychopharmacology guidelines?

Answer: Risperidone

Here is one slide from this presentation explaining the answer

The role of atypical antipsychotics for MDD augmentation will be discussed in the following sections:

CHAPTER 1: ATYPICAL ANTIPSYCHOTICS FOR MDD AUGMENTATION

(FOR ACADEMY MEMBERS ONLY)

INTERESTED IN LEARNING MORE?

JOIN ACADEMY’S FIRST LECTURE SERIES OF 2023:

PSYCHIATRY EDUCATION FORUM ACADEMY'S
JANUARY 2023 LECTURE SERIES ANNOUNCEMENT
(JAN 14 - JAN 29, 2023)

MAJOR DEPRESSIVE DISORDER:
10 AUGMENTATION STRATEGIES

Major Depressive Disorder: 10 Augmentation Strategies

JOIN ACADEMY MEMBERSHIP:

GENERAL
$ 99/YR
  •  
STUDENTS
$ 75/YR
  •  

DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.

Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com

Related Articles

Responses

Your email address will not be published. Required fields are marked *